Bastiaan Driehuys

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Bastiaan Driehuys sits in the top decile of US sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count).

16 total trials 8 currently recruiting 8 completed early-phase tilt top decile by trial count

Bastiaan Driehuys: 16 sponsored US clinical trials, 8 recruiting.

Bastiaan Driehuys sponsors 16 registered US clinical trials on ClinicalTrials.gov, 8 of them currently recruiting, and 8 completed. 0 of these trials are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Pulmonary Arterial Hypertension, with 4 trials.

Top-decile sponsor footprint

Bastiaan Driehuys ranks in the top decile of sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

16 total, page 1 of 1

RECRUITING

Downstream Effects of Airway Mucus Plugs on 129Xenon MRI in Severe Asthma

NCT07139899
RECRUITING Phase 2

129 Xenon Imaging in Patients Treated With Sotatercept

NCT06351345
RECRUITING Phase 2

Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia

NCT07037836
RECRUITING Phase 2

129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)

NCT06104228
RECRUITING Phase 2

129Xe MRI Cardiopulmonary

NCT06038630
RECRUITING Phase 2

Pulmonary Hypertension SOLAR

NCT04778046
RECRUITING Phase 2

Xenon MRI Pulm Hypertension

NCT04991454
RECRUITING Phase 2

Hyperpolarized 129Xe MRI for Imaging Pulmonary Function

NCT01280994
COMPLETED Phase 2

Optimizing and Standardizing 129Xe Gas Exchange MRI to Visualize Regional Therapy Response in Interstitial Lung Disease

NCT04855305
COMPLETED Phase 2

Dual MRI for Cardiopulmonary COVID-19 Long Haulers

NCT04828135
COMPLETED Phase 2

Oxidative Stress in Asthma

NCT04512547
COMPLETED Phase 2

Effects of Bevespi on Ventilation and Gas Exchange Abnormalities in COPD Assessed by 129Xe MRI

NCT03324607
COMPLETED Phase 2

Assessing Response to Inhaled Prostacyclin With Hyperpolarized Xe MRI

NCT03367312
COMPLETED Phase 2

Non-Invasive Diagnosis of Pulmonary Vascular Disease Using Inhaled 129Xe Magnetic Resonance Imaging

NCT03078192
COMPLETED Phase 2

Longitudinal MR Imaging of Pulmonary Function in Patients Receiving Thoracic Radiation Treatment

NCT02478255
COMPLETED Phase 1

Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis

NCT02478268

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 14

Therapeutic Areas

Pulmonary Arterial Hypertension 4
Interstitial Lung Disease 3
Pulmonary Hypertension 2
Dyspnea 1
Polycythemia 1
Acute Pulmonary Embolism 1
Chronic Thromboembolic Pulmonary Hypertension 1
Connective Tissue Diseases 1
Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (Disorder) 1
COPD (Chronic Obstructive Pulmonary Disease) 1

What is open in the Bastiaan Driehuys pipeline

8 recruiting of 16 indexed (50% open); 8 completed (50%).

Phase mix: 0 late (III/IV) vs 15 early (I/II) (early-phase heavy).

Top condition: Pulmonary Arterial Hypertension (4 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Bastiaan Driehuys: open-pipeline peers nationwide

Peers matched on 16 registered trials and 50% open enrollment, not the therapeutic-area sidebar.

Bastiaan Driehuys sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05101520 0%20%40%60% Total trials Recruiting share Bastiaan DriehuysAccelerated Community Oncology Research NetworkAltimmuneAmerican UniversityAnthera Pharmaceuticals1200 Pharma1ST Biotherapeutics3ive Labs60 Degrees Pharmaceuticals
Bastiaan Driehuys sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Bastiaan Driehuys sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 16 trials (± recruiting share)

Sponsors near 50% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Bastiaan Driehuys page

16 registered trials is a research-attention snapshot, not an endorsement of Bastiaan Driehuys or any single study.

  • 8 of Bastiaan Driehuys's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Pulmonary Arterial Hypertension is the condition Bastiaan Driehuys studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Pulmonary Arterial Hypertension trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Bastiaan Driehuys pipeline card: 16 registered trials from official public datasets.Report a data error.